Cataract News and Research RSS Feed - Cataract News and Research

A cataract is a clouding of the lens in the eye that affects vision. Most cataracts are related to aging. Cataracts are very common in older people. By age 80, more than half of all Americans either have a cataract or have had cataract surgery.

A cataract can occur in either or both eyes. It cannot spread from one eye to the other.
TKCI outlines plan to curb corneal blindness worldwide by 2030

TKCI outlines plan to curb corneal blindness worldwide by 2030

The Tej Kohli Cornea Institute in partnership with the world-renowned LV Prasad Eye Institute, has today laid out its plan to control corneal blindness, globally, by 2030. [More]
New data from studies evaluating diagnostic tools, therapies for infectious diseases released at ECCMID 2016

New data from studies evaluating diagnostic tools, therapies for infectious diseases released at ECCMID 2016

New data from ten late-breaking abstracts is released at ECCMID 2016 – the annual meeting of the European Society of Clinical Microbiology and Infectious Disease. [More]
Increased expression of VEGF-A promotes three common aging-related eye conditions

Increased expression of VEGF-A promotes three common aging-related eye conditions

A Massachusetts General Hospital investigator has found that increased expression of the angiogenic factor VEGF-A promotes three common aging-related eye conditions - both versions of age-related macular degeneration (AMD) and also cataracts - in an animal model. [More]
Diet and lifestyle may play greater role than genetics in cataract development, severity

Diet and lifestyle may play greater role than genetics in cataract development, severity

A diet rich in vitamin C could cut risk of cataract progression by a third, suggests a study being published online today in Ophthalmology, the journal of the American Academy of Ophthalmology. The research is also the first to show that diet and lifestyle may play a greater role than genetics in cataract development and severity. [More]
New, regenerative medicine approach developed to remove congenital cataracts in infants

New, regenerative medicine approach developed to remove congenital cataracts in infants

Researchers at University of California, San Diego School of Medicine and Shiley Eye Institute, with colleagues in China, have developed a new, regenerative medicine approach to remove congenital cataracts in infants, permitting remaining stem cells to regrow functional lenses. [More]
Study reveals another clue to workings of trachoma

Study reveals another clue to workings of trachoma

Another clue to the workings of trachoma - the world's leading infectious cause of blindness - has been revealed in a new study published in BMC Infectious Diseases. Researchers identified markers of genetic regulation present in the early stages of infection that could predispose children to developing the condition in its long-term, severe form. [More]
Shire announces resubmission of lifitegrast NDA to FDA for treatment of dry eye disease in adults

Shire announces resubmission of lifitegrast NDA to FDA for treatment of dry eye disease in adults

Shire plc today announced it has resubmitted the New Drug Application (NDA) to the U.S. Food and Drug Administration for its investigational candidate, lifitegrast, for the treatment of signs and symptoms of dry eye disease in adults. Shire resubmitted the NDA in response to the complete response letter (CRL) the company received from the FDA on October 16, 2015. [More]
Dynamic light scattering technique may help detect people at risk of cataracts and presbyopia

Dynamic light scattering technique may help detect people at risk of cataracts and presbyopia

As we age, proteins in the lenses of our eyes start misbehaving: They unfold and congregate in clusters that block, scatter and distort light as it passes through the lens. A cloudy area, or cataract, forms. In a new study, scientists found that throughout our lifetime, levels of a key protein decline, and may be an early warning sign of a developing cataract. [More]

ALPHAEON completes acquisition of LENSAR

ALPHAEON Corporation, a social commerce company and subsidiary to Strathspey Crown Holdings LLC, today announced it has closed on its acquisition of LENSAR, Inc., a leading global developer and manufacturer of Femtosecond Lasers Systems (FLS), through a wholly owned subsidiary. Terms of the acquisition were not disclosed. [More]
Adverse environmental changes present potential health hazards to eyes

Adverse environmental changes present potential health hazards to eyes

Another reason to worry about climate change: Expanding areas of arid land, air pollution, and greater exposure to ultraviolet (UV) radiation all present potential health hazards to your eyes, according to Sheila West, Ph.D., vice chair for research at the Wilmer Eye Institute, Johns Hopkins University. [More]

ALPHAEON signs agreement with PhysIOL to develop and commercialize Trifocal lens technology

ALPHAEON Corporation today announced it has entered into a definitive agreement with PhysIOL SA of Belgium, to jointly develop and commercialize an exclusive ALPHAEON-branded Trifocal lens technology. Specific terms of the agreement were not disclosed. [More]
UCSF scientists identify eye drop chemical that may reverse cataracts

UCSF scientists identify eye drop chemical that may reverse cataracts

A chemical that could potentially be used in eye drops to reverse cataracts, the leading cause of blindness, has been identified by a team of scientists from UC San Francisco (UCSF), the University of Michigan (U-M), and Washington University in St. Louis (WUSTL). [More]
Saint Louis University ophthalmologist offers tips to manage night vision issues

Saint Louis University ophthalmologist offers tips to manage night vision issues

Owls and cats are at an advantage as the days get darker, but humans may notice their vision takes a hit during their evening commute home as daylight hours shrink. [More]
Allergan completes acquisition of AqueSys

Allergan completes acquisition of AqueSys

Allergan plc, a leading global pharmaceutical company, today announced that it has successfully completed the acquisition of AqueSys, Inc. a clinical-stage medical device company focused on developing ocular implants that reduce intraocular pressure (IOP) associated with glaucoma. [More]
Omeros launches OMIDRIAssure program to provide expanded patient access to Omidria

Omeros launches OMIDRIAssure program to provide expanded patient access to Omidria

Omeros Corporation today announced that it has launched OMIDRIAssure, a comprehensive reimbursement services program to provide expanded access to Omidria® (phenylephrine and ketorolac injection) 1% / 0.3% for cataract surgery patients and reimbursement assistance for physicians and facilities. [More]
ILUVIEN continues to show positive results in Europe

ILUVIEN continues to show positive results in Europe

Alimera Sciences Limited, the European subsidiary of Alimera Sciences, Inc., a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, announced the availability of real world data from 28 injections of ILUVIEN (Fluocinolone Acetonide 190 micrograms intravitreal implant in applicator) in Europe, presented in a review paper authored by Fahd Quhill, Consultant Ophthalmologist, Department of Ophthalmology, Royal Hallamshire Hospital, Sheffield, South Yorkshire, U.K. [More]
Alimera Sciences announces results from ongoing study on ILUVIEN

Alimera Sciences announces results from ongoing study on ILUVIEN

Alimera Sciences, Inc., a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, announced that Alimera Sciences Limited, its European subsidiary based in London, revealed interim six-month data on ILUVIEN (Fluocinolone Acetonide 190 micrograms intravitreal implant in applicator) from the ongoing study referred to as RESPOND, a non-Randomised, open-label, multicenter phase 4 pilot study on the Effect and Safety of ILUVIEN Fluocinolone Acetonide in chronic diabetic macular edema Patients cOnsidered iNsufficiently responsive to available therapies with or without intravitreal corticosteroiD therapy. [More]
UK’s GPs, optometrists confirm link between smoking and loss of vision

UK’s GPs, optometrists confirm link between smoking and loss of vision

Smokey eyes are regarded as sexy, sultry and stunning. But nothing could be further from the truth, according to new research unveiled this National Eye Health Week. [More]

IRIDEX launches novel intra-ocular pressure monitoring device

IRIDEX Corporation today announced that it has added a novel intra-ocular pressure (IOP) monitoring device called a tonometer to its suite of commercial products for the global glaucoma market. The new device comes to IRIDEX through a distribution agreement with Icare Finland Plc, a subsidiary of the Revenio Group Corporation, the creator of the tonometer. [More]
Allergan enters into agreement to acquire Aquesys and its XEN45 program

Allergan enters into agreement to acquire Aquesys and its XEN45 program

Allergan plc, a leading global pharmaceutical company, and AqueSys, Inc. a private clinical stage medical device company focused on developing ocular implants that reduce intraocular pressure (IOP) associated with glaucoma, today announced that they have entered into an agreement under which Allergan will acquire AqueSys in an all-cash transaction. [More]
Advertisement
Advertisement